Ototoxic Drugs Typically Cause Bilateral Hearing Loss
Ototoxic medications predominantly cause bilateral (both-sided) hearing loss, not unilateral damage. This is the characteristic pattern seen with most systemically administered ototoxic agents.
Pattern of Hearing Loss by Drug Class
Platinum-Based Chemotherapy
The most extensively studied ototoxic agents—cisplatin, carboplatin, and oxaliplatin—consistently produce bilateral hearing loss 1. The damage occurs symmetrically because these drugs are delivered systemically and affect both cochleae through the bloodstream. The hearing loss typically begins at high frequencies (4-8 kHz) and can progress to lower frequencies with continued exposure.
Immunosuppressants
Calcineurin inhibitors (cyclosporine and tacrolimus) also predominantly cause bilateral hearing loss 2. Among 128 cases of hearing loss related to immunosuppressant therapy, the vast majority were bilateral. This bilateral pattern is particularly associated with elevated serum drug levels.
Aminoglycosides and Other Antibiotics
While not extensively detailed in the provided guidelines, aminoglycosides follow the same bilateral pattern when causing ototoxicity 3, 4. The systemic distribution of these drugs results in symmetric cochlear damage.
Loop Diuretics
Furosemide and bumetanide demonstrate significant bilateral ototoxic effects, especially when combined with other ototoxic medications 4.
Why Bilateral Damage Occurs
The bilateral nature of drug-induced ototoxicity reflects the mechanism of delivery:
- Systemic circulation distributes the drug equally to both inner ears
- Cochlear hair cells in both ears are exposed to similar drug concentrations
- Symmetric vulnerability of sensory structures on both sides
Important Clinical Caveat
Asymmetric or unilateral hearing loss should raise suspicion for causes other than typical drug ototoxicity. One case report described asymmetric hearing loss with aspirin intoxication (50 dB loss), but this is exceptional rather than typical 5. When you encounter unilateral hearing loss in a patient on ototoxic medications, consider:
- Concurrent pathology (acoustic neuroma, Meniere's disease, sudden sensorineural hearing loss)
- Infection
- Vascular events
- Other non-drug-related causes
Monitoring Implications
Because ototoxicity is characteristically bilateral:
- Test both ears during surveillance audiometry 1
- Compare symmetry between ears—significant asymmetry warrants additional investigation
- Use pure-tone audiometry at frequencies between 250-16,000 Hz to detect early bilateral high-frequency loss 1
- Serial testing is essential as bilateral damage may progress with continued exposure
The bilateral pattern is so consistent that it serves as a diagnostic feature: symmetric, high-frequency sensorineural hearing loss in a patient receiving known ototoxic drugs strongly suggests drug-induced damage rather than other etiologies.